M890119
102

UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D.C. 20555

February 10, 1989

MEMORANDUM FOR: Victor Stello, Jr.
Executive Director for Operations

FROM: Samuel J. Chilk, Secretary

SUBJECT: STAFF REQUIREMENTS - BRIEFING ON MEDICAL USE OF BY-PRODUCT MATERIALS, 10:00 A.M., THURSDAY, JANUARY 19, 1989, COMMISSIONERS' CONFERENCE ROOM, ONE WHITE FLINT NORTH, ROCKVILLE, MARYLAND (OPEN TO PUBLIC ATTENDANCE)

The Commission* was briefed by the staff on current and future activities for monitoring and improving public health and safety in the medical uses of nuclear by-product materials.

The Commission requested the staff to:

-- Review the need for increasing the inspection frequency of community hospitals.

-- Determine if Agreement States meet NRC's minimum frequency of inspection guidelines and review the programs of states which exceed staff's goal of a minimum of one inspection every three years (including their rationale and need for greater frequency of inspection).
(EDO) (SECY Suspense: 3/3/89)

-- Retain the rigor of reporting requirements for misadministrations in any proposed redefinition of this term. The rationale for any such redefinition should be provided in the staff paper accompanying the proposed rule on quality assurance and reporting requirements of misadministrations, unless staff believes the issue must be resolved on a higher priority basis.
(EDO) (SECY Suspense: 4/28/89)

* Commissioners Rogers and Curtiss were not present.

Ä 2 Ä

103

-- Submit an information paper which outlines staff's activities in the following areas (as previously requested by commissioner Rogers).

(1) Efforts in monitoring medical community performance and the development of indicators of trends in performance.

(2) Discussions with the medical community on establishing a visiting fellows program with NMSS, including the associated costs of such a program.
(EDO) (SECY Suspense: 4/14/89)

-- Provide a status briefing on NRC activities for improving oversight of medical use licensees.
(EDO) (SECY Suspense: 7/89)

-- Interact with the Advisory Committee on the Medical Uses of Isotopes in developing the performance evaluation factors which the staff proposes to submit to the commission in September 1989.
(EDO) (SECY Suspense: 9/89)

-- Review the U.S. Food and Drug Administration's (FDA's) quality assurance requirement and regulatory experiences for possible application by the NRC.

-- Ensure highly qualified NRC inspectors and professional

inspection programs.

-- Propose, in the Commission's Five Year Plan, the necessary resource adjustments believed appropriate to respond to the concerns outlined in the Commission briefing (e.g., computerized treatment planning, availability of trained

technologists, monoclonal antibodies, etc.).

-- Work closely with the Agreement States to ensure that any proposed requirements affecting NRC's medical use licensees are compatible with requirements for those activities regulated by the Agreement States.

Commissioner Carr noted that the staff has shown good initiative in activities intended to improve oversight of the medical use of by-product material. He urged the staff to continue making progress in this important area.

cc: Chairman Zech
Commissioner Roberts
Commissioner Carr
Commissioner Rogers
Commissioner Curtiss
OGC
GPA
PDR Ä Advance
DCS Ä P1-124